Thorpe, Cheleste M <br/><br/>
Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin.  [electronic resource] 

 -  PloS one  2018 
 - e0199810 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0199810  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Actinobacteria--drug effects<br/>Anti-Bacterial Agents--pharmacology<br/>Benzimidazoles--pharmacology<br/>Clostridioides difficile--drug effects<br/>Clostridium Infections--drug therapy<br/>Cohort Studies<br/>DNA, Bacterial--chemistry<br/>Discriminant Analysis<br/>Feces--microbiology<br/>Firmicutes--drug effects<br/>Gastrointestinal Microbiome--drug effects<br/>Humans<br/>Principal Component Analysis<br/>Proteobacteria--drug effects<br/>Pyridines--pharmacology<br/>Vancomycin--pharmacology